https://imedsciences.com/ editor_ijims@hotmail.com
ISSN: 2394-4137 (E) 2394-6318 (P)

IJIMS.2016.150

Type of Article: Original Research

Volume 3; Issue 10: October 2016

Page No.: 427-432

DOI: 10.16965/ijims.2016.150

An Interventional Follow up Study to Determine the Effect of Nepafenac 0.1% in Macular thickness in Patients who had Undergone Cataract Surgery as Determined By OCT

Rama Vadapalli *1, Vankadara Naga Suresh 2.

*1 Assistant Professor, Department of Ophthalmology, Santhiram Medical College, Nandyal, Andhra Pradesh, India.
2 Associate Professor, Department of Ophthalmology, Viswa Bharathi Medical College, Kurnool, Andhra Pradesh, India.

CORRESPONDING AUTHOR ADDRESS: Dr. Rama Vadapalli. Assistant Professor, Department of Ophthalmology, Santhiram Medical College, Nandyal, Andhra Pradesh, India. E-Mail: ramav1728@gmail.com

ABSTRACT

Background: Pseudophakic cystoid macular edema (CME) also known as Irvine-Gass syndrome, is one of the most common causes of visual loss after cataract surgery. Pathogenesis is thought to involve the release of inflammatory mediators, and non steroidal anti-inflammatory medications are often used for CME prophylaxis. The aim of the study is to determine the role of Nepafenac 0.1% usage in altering the status of CME as determined by OCT who underwent Cataract Surgery.

Materials and Methods: A total of 100 subjects with a 1:1 control: Treatment ratio that underwent small incision cataract surgery (SICS), Subjects were randomised in to 50 control group (standard of care only) and 50 treatment group (Standard of care plus nepafenac). Immediate post operatively, OCT scans were carried out on 1st post-operative day and at 4 weeks, using the macular thickness protocol with the stratus OCT version 5.0.1 at Santhiram General Hospital, Nandyal, between 2012- 15.

Results: In present study, the results demonstrated that with usage of postoperative topical nepafenac 0.1% there were differences between the treatment group and control group regarding the OCT measured macular thickness. After analysing the data and applying appropriate statistical analysis it can be concluded that 0.1% Nepafenac can be used as a treatment option for primary CME in post cataract patients. Topical therapy of 0.1% Nepafenac related side effects like Keratitis, corneal melt & corneal perforation are very rare and were not encountered in any patient in our study.

Conclusion: In our study, results concluding that the topical nepafenac 0.1% therapy has promising results for prevention of pseudophakic cystoid macular edema.

KEY WORDS: cystoid macular edema, OCT, macular thickness, Nepafenac 0.1%.

REFERENCES

  1. Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24:371–84
  2. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000;24:357–70
  3. Lindstrom R, Kim T (2006) Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of Nepafenac. Curr Med Res Opin 22: 397-404.
  4. Perente I, Utine CA, Ozturker C, et al. Evaluation of macular changes after uncomplicated phacoemulsification surgery by optical coherence tomography. Curr Eye Res 2007;32: 241–7.
  5. Nicholas S, Riley A, Patel H, et al. Correlations between optical coherence tomography measurement of macular thickness and visual acuity after cataract extraction. Clin Experiment Ophthalmol 2006;34:124–9.
  6. Ching HY, Wong AC, Wong CC, et al. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye (Lond) 2006;20:297–303.
  7. Shahidi M, Ogura Y, Blair NP, et al. Retinal thickness analysis for quantitative assessment of diabetic macular edema. Arch Ophthalmol. 1991;109:1115-1119.
  8. Nussenblatt RB, Kaufman SC, Palestine AG, et al. Macular thickening and visual acuity. Ophthalmology. 1987;94:1134-1139.
  9. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol. 1995;113:1019-1029.
  10. Hee MR, Puliafito CA, Duker JS, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105:360-370.
  11. Konno S, Akiba J, Yoshida A. Retinal thickness measurements with optical co-
  12. Neubauer AS, Priglinger S, Ullrich S, et al. Comparison of foveal thickness measured with the retinal thickness analyzer and optical coherence tomography. Retina. 2001;21:596-601.
  13. Massin P, Vicaut E, Haouchine B, et al. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol. 2001;119:1135-1142.
  14. Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol. 2004;137:156-169.
  15. Brown JC, Solomon SD, Bressler SB, et al. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol. 2004;122:330-335
  16. Miyake K, Ibaraki N. Prostaglandins and cystoids macular edema. Surv Ophthalmol 2002; 47(suppl 1):S203-S218.
  17. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoids macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147-154.
  18. Hariprasad SM, Callanan D, Gainey S, He YG, Warren K. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther.2007;23:585-590.
  19. Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008;2:689-692.
  20. Rishi Singh, Louis Alpern, Glenn J Jaffe, Robert P Lehmann, John Lim, Harvey J Reiser, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology 2012;6:1259-69.
  21. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoids macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3:147-154.
Download Full Text TOC